Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency

[1]  R. Becker,et al.  Hemostasis and thrombosis in older adults , 2009, Journal of Thrombosis and Thrombolysis.

[2]  D. Angiolillo,et al.  Pharmacology of emerging novel platelet inhibitors. , 2008, American heart journal.

[3]  Bari Investigators.  The final 10-year follow-up results from the BARI randomized trial. , 2007 .

[4]  R. Shah,et al.  Spontaneous late thrombolysis of an occluded saphenous vein graft subsequent to acute myocardial infarction treated with percutaneous coronary intervention to the native culprit vessel. , 2006, Journal of interventional cardiology.

[5]  G. Montalescot,et al.  The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration , 2005 .

[6]  S. Doggrell.  CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction , 2005, Expert opinion on pharmacotherapy.

[7]  D. Baim.  Percutaneous treatment of saphenous vein graft disease: the ongoing challenge. , 2003, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical Trials , 2002, Circulation.

[9]  D. Freimark,et al.  Improved prognosis of patients presenting with clinical markers of spontaneous reperfusion during acute myocardial infarction , 2002, Heart.

[10]  B. Andersson,et al.  Myocardial ischemia induces coronary t‐PA release in the pig , 2002, Acta anaesthesiologica Scandinavica.

[11]  D. Holmes,et al.  Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. , 2001, American heart journal.

[12]  R. Califf,et al.  Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. , 2001, American heart journal.

[13]  J. J. Griffin,et al.  Clinical and angiographic outcomes in patients with previous coronary artery bypass graft surgery treated with primary balloon angioplasty for acute myocardial infarction , 2000 .

[14]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[15]  J. Jansson,et al.  Predictive Value of Tissue Plasminogen Activator Mass Concentration on Long‐term Mortalit in Patients With Coronary Artery Disease A 7‐Year Follow‐up , 1993, Circulation.

[16]  V. Dangoisse,et al.  Spontaneous thrombolysis in asuboccluded saphenous vein graft , 1990 .

[17]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[18]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[19]  Jin Li-jun,et al.  The final 10-year follow-up results from the BARI randomized trial. , 2007, Journal of the American College of Cardiology.

[20]  V. Dangoisse,et al.  Spontaneous thrombolysis in a suboccluded saphenous vein graft. , 1990, American heart journal.